Some states, such as Texas and Florida, have begun offering shots to non-nursing home residents over the age of 65, and to people of all ages with medical conditions that increase their risk of dying if infected with Covid-19. I will. It has led to a desperate scramble among those who are eager to get vaccinated.
“People want to know: when is my turn? Is this happening? Where should I go?” Murray said.
Even with a smooth distribution twist, so far only two products, one developed by Moderna and one developed by Pfizer-BioNTech, are allowed for emergency use, and vaccine shortages are imminent. I will. Both vaccine manufacturers are committed to all doses until mid-year. Still, about 60 million adult Americans eligible for vaccination have not yet been found.
Authorities are also very excited about the third single-dose vaccine from Johnson & Johnson. The company has completed clinical trials this month and the vaccine may be approved for emergency use in February. However, even if they pass those tests, it is unclear how many more doses are ready for distribution and by when.
Using a suitable syringe, federal officials want to extract additional doses from Pfizer’s vials, which were initially thought to contain only five doses, to further expand Pfizer’s vaccine. .. However, according to two experts familiar with the vaccine distribution system, the government has not yet signed a contract to adequately supply these syringes.
So the prospect of doubling the supply of moderna is much more attractive. Dr. Monsef Slawi, head of Operation Warp Speed, said on Sunday in the CBS program Face the Nation that Moderna’s clinical trial data show that people aged 18-55 years who received two doses of 50 micrograms “same immunity.” To the standard of two 100 microgram doses stated that they showed a “reaction”.
Both Dr. Mascola and Dr. Forch confirmed the study.
But Dr. Slawi went one step further, saying the FDA and Moderna were already discussing that possibility. The FDA released a statement on Monday stating that the proposal was “premature and not firmly rooted in the available science,” but deserves clinical research.
The findings cited by Dr. Slawi came from an early phase II clinical trial involving 600 people and were aimed at testing only the immune response, not the efficacy of the vaccine, Dr. Forch et al. Stated. It compared the immune responses of people who were given 50 micrograms and those who were given 100 micrograms.
Warning of shortage, researchers look to increase vaccine supply
Source link Warning of shortage, researchers look to increase vaccine supply